|Bid||2.0900 x 1100|
|Ask||2.1000 x 3100|
|Day's Range||2.0100 - 2.1200|
|52 Week Range||1.1400 - 2.5900|
|Beta (5Y Monthly)||1.66|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Subscribe to Yahoo Finance Plus to view Fair Value for OTIC
Joining me on the call from Otonomy are Dr. David Weber, president and chief executive officer; and Paul Cayer, chief financial and business officer. Before I turn the call over to Dr. Weber, I would like to remind you that today's call will include forward-looking statements based on current expectations.
Otonomy Inc (NASDAQ: OTIC) announced topline results from the Phase 2a clinical trial of OTO-413 in subjects with hearing loss. The trial demonstrated that a single intratympanic injection of 0.3 mg OTO-413 provided clinically meaningful treatment benefit versus placebo across multiple speech-in-noise (SIN) hearing tests and the Patient Global Impression of Change at consecutive time points (Days 57 and 85). 40% (8 of 20) of OTO-413 subjects demonstrated a clinically meaningful improvement on at
Every investor in Otonomy, Inc. ( NASDAQ:OTIC ) should be aware of the most powerful shareholder groups. Institutions...